Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities

Mahanta, Kinkar; Medhi, Bikash; Kaur, Baljit; Narasimhan, Kannan Laksmi

doi:10.1016/j.jpurol.2007.10.011

Cited by 9 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, a double‐blinded cross‐over trial, as well as a case‐control study, showed no deleterious effect on children's attention and memory . Tolterodine, solifenacin, trospium chloride, and propiverine and their combinations have been used safely in children . It should be stated, however, that all antimuscarinic agents are still off label use in neonates and young children.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment

Stein

Bogaert

Doğan

et al. 2019

Neurourology and Urodynamics

104

View full text Add to dashboard Cite

Background: In childhood, the most common reason for a neurogenic bladder is related to spinal dysraphism, mostly myelodysplasia.Aims: Herein, we present the EAU/ESPU guidelines in respect to the diagnostics, timetable for investigations and conservative management including clean intermittent catheterization (CIC). Material and Methods: After a systematic literature review covering the period 2000 to 2017, the ESPU/EUAU guideline for neurogenic bladder underwent an update. Results: The EAU/ESPU guideline panel advocates a proactive approach. In newborns with spina bifida, CIC should be started as soon as possible after birth. In those with intrauterine closure of the defect, urodynamic studies are recommended be performed before the patient leaves the hospital. In those with closure after birth urodynamics should be done within the next 3 months. Anticholinergic medication (oxybutynin is the only well-investigated drug in this age group-dosage 0.2-0.4 mg/kg weight per day) should be applied, if the urodynamic study confirmed detrusor overactivity. Close follow-up including ultrasound, bladder diary, urinalysis, and urodynamics are necessary within the first 6 years and after that the time intervals can be prolonged, depending on the individual risk and clinical course. In all other children with the suspicion of a neurogenic bladder due to various reasons as tethered cord, inflammation, tumors, trauma, or other reasons as well as those with anorectal malformations, urodynamics-preferable video-urodynamics, should be carried out as soon as there is a suspicion of a neurogenic bladder and conservative treatment should be started soon after confirmation of the diagnosis of neurogenic bladder. With conservative treatment the upper urinary tract is preserved in up to 90%, urinary tract infections are common, but not severe, complications of CIC are quite rare and continence can be achieved at adolescence in up to 80% without further treatment. ORCID Raimund Stein

show abstract

Section: Methodsmentioning

confidence: 99%

“…64,65 Tolterodine, solifenacin, trospium chloride, and propiverine and their combinations have been used safely in children. [66][67][68][69][70][71][72] It should be stated, however, that all antimuscarinic agents are still off label use in neonates and young children.…”

Section: Medical Therapymentioning

confidence: 99%

EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment

Stein

Bogaert

Doğan

et al. 2019

Neurourology and Urodynamics

104

View full text Add to dashboard Cite

show abstract

“…The comparative efficacy and safety of instant-versus extended-release tolterodine in children with NGB due to neural tube defects were evaluated [23]. A total of 25 children were treated with tolterodine extended release, 2 mg once daily, or immediate release, 2 mg twice daily, for 3 weeks in a crossover study with a 10-day washout period.…”

Section: Clinical Studiesmentioning

confidence: 99%

Neurogenic Bladder: Current Pharmacologic Trends

Cameron

Latini

2010

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

Several studies have investigated the many pharmacologic therapies to treat neurogenic bladder. Our aim with this review is to provide an update on the current clinical and basic science literature pertaining to pharmacotherapy for this condition. Advances have been made in pediatric and adult pharmacotherapy. The most notable include the safety and effective use of tolterodine and transdermal oxybutynin in the treatment of pediatric neurogenic bladder. Also, recently, the safe and effective triple drug therapy consisting of an antimuscarinic, an α-blocker, and imipramine in combination has been shown to significantly improve bladder compliance and detrusor pressures.

show abstract

Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia

et al. 2013

View full text Add to dashboard Cite

show abstract

Comparative efficacy and safety of extended-release and instant-release tolterodine in children with neural tube defects having cystometric abnormalities

Cited by 9 publications

References 20 publications

EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment

EAU/ESPU guidelines on the management of neurogenic bladder in children and adolescent part I diagnostics and conservative treatment

Neurogenic Bladder: Current Pharmacologic Trends

Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia

Contact Info

Product

Resources

About